Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sibutramine in overweight or obese subjects at risk of cardiovascular events
NCT00234832Phase 3Completed
- Sponsor
- Abbott Laboratories
- Start
- Jan 2003
- Primary completion
- Mar 2009
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sibutramine in obesity (3 arms), sponsored by Abbott Laboratories. Primary endpoint: Primary Outcome Event at 6 years. Started Jan 2003; status: completed.
02
Drugs
sibutramine
03
Conditions
obesity
Beyond the preview
Go deeper on NCT00234832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00234832.